May 23, 2019 / 4:12 PM / 3 months ago

GSK's shingles vaccine approved for use in China in adults aged 50 and above

May 23 (Reuters) - GlaxoSmithKline Plc said file:///C:/Users/U6070662/AppData/Local/Fastwire/Download/-19962 2621/Press%20Release%20-%20GSK%20announces%20approval%20of%20Shi ngrix%20in%20China%20for%20prevention%20of%20shingles%20in%20adu lts%20aged%2050%20and%20over%2023052019.pdf on Thursday its shingles vaccine had been approved for use in China in adults aged 50 and above.

Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds ($452.03 million) in the latest quarter.

The company said the vaccine will be introduced in phases, starting in 2020 to ensure reliable supply to all countries, where it has been launched.

$1 = 0.7898 pounds Reporting by Samantha Machado in Bengaluru; Editing by Anil D'Silva

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below